TY  - JOUR
AU  - Poveda, Andres
AU  - Lopez-Reig, Raquel
AU  - Oaknin, Ana
AU  - Redondo, Andres
AU  - Rubio, Maria Jesus
AU  - Guerra, Eva
AU  - Fariñas-Madrid, Lorena
AU  - Gallego, Alejandro
AU  - Rodriguez-Freixinos, Victor
AU  - Fernandez-Serra, Antonio
AU  - Juan, Oscar
AU  - Romero, Ignacio
AU  - Lopez-Guerrero, Jose A
PY  - 2022
DO  - 10.3390/cancers14040915
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/20873
T2  - Cancers
AB  - We hypothesized that the combination of olaparib and lurbinectedin maximizes DNA damage, thus increasing its efficacy. The POLA phase 1 trial established the recommended phase 2 dose of lurbinectedin as being 1.5 mg (day 1) and that of olaparib as...
LA  - en
KW  - endometrial cancer
KW  - genomic instability
KW  - lurbinectedin
KW  - olaparib
KW  - ovarian cancer
TI  - Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
TY  - research article
VL  - 14
ER  -